EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Malaysian Genomics Resource (0155) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Malaysian Genomics Resource MYR 0.17, price MYR 0.35, upside -51.4%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · MY · ISIN MYQ0155OO000

MG Thin data Sep 24, 2026

Malaysian Genomics Resource

0155 · KLSE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value 0.1700 MYR · Strongly overvalued (−51%)
✓Quality 69/100
!Mixed Growth (revenue 5y +35.1 %/yr)
!Loss-making · -5.3% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (6/12)
!Narrow moat 31/100
!Evidence only low, so the estimate is less certain
Watch Malaysian Genomics Resource for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2.72 MYR 0.1450 MYR Fair Value 0.1700 MYR May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 0.1450 MYR – 2.72 MYR · fair‑value band 0.0900 MYR – 0.2600 MYR · the 0.3500 MYR price screens above the 0.1700 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Malaysian Genomics Resource in your weekly email

Every Wednesday you see whether Malaysian Genomics Resource is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia.

Show more

Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia. The company offers genetic screening services that includes Dtect and Origene genetic testing solutions which provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits. It also provides immunotherapy and cell therapy which offers mesenchymal stem cells derived from ethically sourced human umbilical cords, as well as natural killer cell therapies designed to strengthen the body's immune response that are relevant in the treatment of cancers, autoimmune diseases, and other complex conditions. In addition, the company offers genome sequencing and bioinformatics services; personalized supplements; cellular therapy for regenerative health; and cell-free therapy for regeneration and repair. Further, it is involved in dealing in capital markets and derivative instruments; acting as general merchants; research, development, and commercialization of biopharmaceutical products and services; business relating to life sciences/cell lab and by products; and distribution of healthcare products, beauty products, and precision medicine. Additionally, the company provides system developments and information technology comprising software and hardware, as well as other human health services and general medical services. Malaysian Genomics Resource Centre Berhad was incorporated in 2004 and is headquartered in Petaling Jaya, Malaysia.

Stock analysis

Malaysian Genomics Resource (0155) currently trades at 0.3500 MYR, while our model-based Fair Value estimate is 0.1700 MYR, implying the stock looks roughly 105.9% overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.1700 MYR per share, and 0 of the 10 models we run sit above the 0.3500 MYR price.

Bear case: the Asset-Based group reads lowest at 0.0700 MYR, and 10 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.0900 MYR (bear) to 0.2600 MYR (bull), the price of 0.3500 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Malaysian Genomics Resource reported revenue of 8.0M MYR in FY2026 versus 28.4M MYR in FY2022, a compound −27.1%/yr. Reported net income was −2.4M MYR in FY2026.

Key figures

Market cap 48.0M MYR (≈ $11.8M) · P/S ratio 4.69 · Net margin −29.7% · Return on equity −5.1% · Return on assets (EBIT) −27.9% · Operating margin 40.4% · Revenue (TTM) 9.3M MYR · Revenue growth (YoY) +96.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 106% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −51%, 0155 screens richer than that median.

Fair Value models

Bear 0.0900 MYR Fair Value 0.1700 MYR Bull 0.2600 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 0.1200 MYR 0.1900 MYR 0.3800 MYR 72
Growth DCF 0.1200 MYR 0.2200 MYR 0.3800 MYR 71
5Y EBITDA Exit 0.0800 MYR 0.1200 MYR 0.2100 MYR 69
All 10 models by family
DCF Models
FCF DCF 0.1200 MYR 0.1900 MYR 0.3800 MYR 72
5Y Revenue Exit 0.0900 MYR 0.1500 MYR 0.2600 MYR 66
5Y EBITDA Exit 0.0800 MYR 0.1200 MYR 0.2100 MYR 69
10Y Revenue Exit 0.1000 MYR 0.2000 MYR 0.2600 MYR 63
10Y EBITDA Exit 0.0900 MYR 0.1700 MYR 0.3100 MYR 61
Multiples
EV/EBITDA 0.0600 MYR 0.0800 MYR 0.0900 MYR 67
EV/Revenue 0.0700 MYR 0.1000 MYR 0.1200 MYR 54
Asset-Based
NCAV (Graham) 0.0500 MYR 0.0700 MYR 0.1000 MYR 54
Growth DCF
Growth DCF 0.1200 MYR 0.2200 MYR 0.3800 MYR 71
Rev-Margin DCF 0.1000 MYR 0.1700 MYR 0.3100 MYR 65

Open the full fair value analysis →

Notify me when 0155 reaches fair value

Put 0155 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 69/100

Of which business quality 67 · Market factors (momentum, volatility) 82

Profitability 15
Margins and returns on capital today
Quality Growth 94
Are margins and returns improving?
Cashflow 70
Earnings quality: real cash, not paper profit
Fin. Strength 76
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 97
Price trend over the last 3–12 months (market factor)
52W Momentum 93
Distance to the 52-week high (market factor)
Net Issuance 73
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+45.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.1%
Start year 2021 (pandemic). Over 10 years: −2.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−235.5% (2021) → −9.1% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +24.4% a year for the price.

0155 screens 106% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Malaysian Genomics Resource with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 69 · Top 25%
Fair Value upside −51% · Below median
Profitability
Return on assets −1% · Below median
Net margin (TTM) −5% · Below median
Operating margin (TTM) 40% · Top 25%
Growth and dividend
Revenue growth 97% · Top 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.75× · Cheaper than median
P/S (TTM) 1.26× · Cheaper than median
P/FCF 11.4× · Pricier than median
EV/EBITDA 15.6× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)0 · sector 8
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $678.39 $686.04 +1%
Danaher Corporation DHR $223.77 $209.18 −7%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Malaysian Genomics Resource · Fair Value
0.1700 MYR −106%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Malaysian Genomics Resource Fair Value". https://www.fairvalue-calculator.com/stock/0155

Frequently asked questions

Is Malaysian Genomics Resource (0155) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.1700 MYR versus a price of 0.3500 MYR, about −51% upside (overvalued).
What is the fair value of 0155?
Our model-based fair value for Malaysian Genomics Resource is 0.1700 MYR (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.3500 MYR.
What is the quality score of 0155?
Malaysian Genomics Resource has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Malaysian Genomics Resource (0155)?
Our model-based price target is the fair value of 0.1700 MYR (as of Sep 24, 2026) from 10 valuation models. Cautious scenario 0.0900 MYR, optimistic scenario 0.2600 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Malaysian Genomics Resource stock forecast for 2026?
Our models put fair value at 0.1700 MYR, about −51% upside versus a price of 0.3500 MYR (overvalued). Cautious scenario 0.0900 MYR, optimistic scenario 0.2600 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Malaysian Genomics Resource (0155)?
Malaysian Genomics Resource reported trailing-twelve-month revenue of about 9.3M MYR (latest available figure, as of Sep 24, 2026).
What growth is priced into Malaysian Genomics Resource (0155)?
For today's price to be fair in a discounted-cash-flow model, Malaysian Genomics Resource would have to grow free cash flow by +26.9 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0155 use?
Our models discount Malaysian Genomics Resource at 9.7 %: a base by market capitalisation (nano), damped by beta 0.08, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Malaysian Genomics Resource that is +26.9 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Malaysian Genomics Resource (0155) delivered so far?
Over the past 5 years revenue at Malaysian Genomics Resource grew +35.1 % a year. The price currently implies +26.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Malaysian Genomics Resource (0155) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Malaysian Genomics Resource (+26.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Malaysian Genomics Resource (0155)?
The free-cash-flow yield on the price is 2.15 %: that much free cash flow Malaysian Genomics Resource produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Malaysian Genomics Resource (0155)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Malaysian Genomics Resource it is 0.1700 MYR per share (as of Sep 24, 2026), against a price of 0.3500 MYR. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Malaysian Genomics Resource stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0155 trades above its calculated fair value: price 0.3500 MYR, fair value 0.1700 MYR, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0155?
No. The price is what the market pays today (0.3500 MYR); the fair value is what the company's own numbers justify (0.1700 MYR). For Malaysian Genomics Resource the two are 0.1800 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Malaysian Genomics Resource worth?
The market values Malaysian Genomics Resource at about 48.0M MYR (market capitalisation, as of Sep 24, 2026). Per share that is 0.3500 MYR; our models calculate a fair value of 0.1700 MYR per share.
What do the bullish and bearish scenarios say about 0155?
Our models span a range for Malaysian Genomics Resource: cautious scenario 0.0900 MYR, base 0.1700 MYR, optimistic 0.2600 MYR per share (as of Sep 24, 2026, price 0.3500 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Malaysian Genomics Resource (0155)?
Balance-sheet figures for Malaysian Genomics Resource (as of Sep 24, 2026): return on equity −5.1%. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 0155 from its 52-week high?
Malaysian Genomics Resource trades at 0.3500 MYR, about 8% below its 52-week high of 0.3800 MYR and 106% above the low of 0.1700 MYR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1700 MYR is for.
Which stocks are comparable to Malaysian Genomics Resource?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Malaysian Genomics Resource stock attractive at the current price?
The data as of Sep 24, 2026: price 0.3500 MYR, calculated fair value 0.1700 MYR (−51%), Quality Score 69/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0155 calculated?
We run Malaysian Genomics Resource through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.1700 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Malaysian Genomics Resource itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Malaysian Genomics Resource (0155)?
The closing price on Sep 24, 2026 was 0.3500 MYR. Our model-based fair value is 0.1700 MYR, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Malaysian Genomics Resource right now?
The price sits above even our optimistic bull case (0.2600 MYR). The favourable scenario is already priced in. The model range is unusually wide (0.0900 MYR to 0.2600 MYR). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Malaysian Genomics Resource

How large is the market capitalisation of Malaysian Genomics Resource (0155)?
The market capitalisation of Malaysian Genomics Resource is 48.0M MYR (≈ $11.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Malaysian Genomics Resource (0155)?
The price-to-sales ratio of Malaysian Genomics Resource is 4.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Malaysian Genomics Resource (0155)?
The net margin of Malaysian Genomics Resource is −29.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Malaysian Genomics Resource (0155)?
The return on equity (ROE) of Malaysian Genomics Resource is −5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Malaysian Genomics Resource (0155)?
On an EBIT basis the return on assets of Malaysian Genomics Resource is −27.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Malaysian Genomics Resource (0155)?
The operating margin of Malaysian Genomics Resource is 40.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Malaysian Genomics Resource (0155)?
Revenue at Malaysian Genomics Resource is growing +96.7% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Malaysian Genomics Resource (0155) carry?
The net debt of Malaysian Genomics Resource is 6.1M MYR (fiscal year 2019, ≈ 5.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Malaysian Genomics Resource in the live analysis

One click puts Malaysian Genomics Resource on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.